Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 4/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | GSTK1 | Q9Y2Q3 | 2/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.44 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.44 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.42 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycerin SCHEMBL4959228 | 0.98 | FOLH1 (0.67) | FOLH1LMNATSHRNFKB1PMP22 | |
| Glycerin SCHEMBL4958002 | 0.93 | FOLH1 (0.58) | FOLH1LMNATSHRNFKB1PMP22 | |
| Glycerin SCHEMBL6048257 | 0.91 | FOLH1 (0.57) | FOLH1LMNATSHRNFKB1PMP22 | |
| Adipic Acid SCHEMBL28688445 | 0.89 | LMNA (0.61) | FOLH1LMNATSHRNFKB1PMP22 | |
| Adipic Acid SCHEMBL270756 | 0.89 | LMNA (0.61) | FOLH1LMNATSHRNFKB1PMP22 | |
| Azelaic Acid SCHEMBL1495263 | 0.86 | TSHR (0.63) | LMNATSHRNFKB1PMP22FFAR1 | |
| Pimelic Acid SCHEMBL29894654 | 0.86 | TSHR (0.63) | LMNATSHRNFKB1PMP22FFAR1 | |
| Sebacic Acid SCHEMBL31652315 | 0.86 | TSHR (0.63) | LMNATSHRNFKB1PMP22FFAR1 | |
| Glycerin SCHEMBL28489790 | 0.86 | TSHR (0.63) | LMNATSHRNFKB1PMP22FFAR1 | |
| Azelaic Acid SCHEMBL31615119 | 0.86 | TSHR (0.63) | LMNATSHRNFKB1PMP22FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080206153-A1 | Copolymers for Cosmetic Agents, Produced in the Presence of Polyfunctional Chain Transfer Agents | BASF AKTIENGESELLSCHAFT (DE) | 2008-08-28 | — | — | US | disclosed |
| EP-1844081-A1 | COPOLYMERS FOR COSMETIC AGENTS, PRODUCED IN THE PRESENCE OF POLYFUNCTIONAL CHAIN TRANSFER AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006077144-A1 | COPOLYMERS FOR COSMETIC AGENTS, PRODUCED IN THE PRESENCE OF POLYFUNCTIONAL CHAIN TRANSFER AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080206153-A1 | Copolymers for Cosmetic Agents, Produced in the Presence of Polyfunctional Chain Transfer Agents | ACOX3, PAOX, ACOT7 | FOLH1 4128/4885LMNA 3541/4885TSHR 2785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.